Aspirin: Old drug, new uses and challenges

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 426-431

  Yeomans, Neville D ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Aspirin; Cancer; Cardiovascular disease; History; Inflammation; Peptic ulcer; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENACETIN; PHENYLBUTAZONE; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID DERIVATIVE;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; DUODENUM INJURY; DUODENUM ULCER; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEART PROTECTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LOW DRUG DOSE; MEDICAL LITERATURE; NONHUMAN; PEPTIC ULCER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC FEVER; STOMACH EROSION; STOMACH INJURY; STOMACH MUCOSA INJURY; STOMACH ULCER; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION INHIBITION; ULCER;

EID: 79951656816     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06569.x     Document Type: Article

References (54)

1. Breasted JH. The Edwin Smith Papyrus. Chicago: The University of Chicago Press, 1930.
2. Anonymous. Willow. Cited 14 Sept 2010. Available from URL: .
3. Gerhardt C. Traité De Chimie Organique. Paris: Firmin Didot Frères, 1853.
4. Childs PE. The centenary of aspirin: wonder drug of the twentieth century. Cited 15 Sept 2010. Available from URL: .
5. Osler W. The Principles and Practice of Medicine, 8th edn. New York: Appleton and Co., 1909.
6. Anonymous. The treatment of acute rheumatic fever in children: a cooperative clinical trial of ACTH, cortisone and aspirin. Circulation 1955; 11: 343-77.
7. Kaplan EL. Rheumatic fever. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill, 2001; 1340-3.
8. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature New Biol. 1980; 284: 271-3.
9. Weiss HJ, Aledort LM. Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet 1967; 2: 495-7.
10. Blatrix C. [Prolonged bleeding time under the influence of certain drugs]. Nouv. Rev. Fr. Hematol. 1963; 3: 346-50.
11. Elwood PC, Cochrane AL, Burr ML etal. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1974; 1: 436-40.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002; 324: 71-86.
13. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751-3.
14. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988; 48: 4399-404.
15. Rostom A, Dube C, Lewin G, Rostom A, Dube C, Lewin G. Use of Aspirin and NSAIDs to prevent colorectal cancer: an evidence synthesis. Prepared for the Agency for Healthcare Research and Quality by the University of Ottawa Evidence-based Practice Center at the University of Ottawa, Ottawa Canada, under Contract No. 290-02-0021. AHRQ Publication No. 07-0596-EF-1. Rockville, Maryland: Agency for Healthcare Research and Quality. March 2007.
16. Din FVN, Theodoraou E, Farrington SM etal. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-9.
17. Baron JA, Sandler RS, Bresalier R etal. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-82.
18. Arber N, Eagle CJ, Spicak J etal. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006; 355: 885-95.
19. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
20. Geall MG, Phillips SF, Summerskill WHJ. Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid. Gastroenterology 1970; 58: 437-43.
21. Yeomans ND. Electron microscopic study of the repair of aspirin-induced gastric erosions. Am. J. Dig. Dis. 1976; 21: 533-41.
22. Hart J, Hawkey CJ, Lanas A etal. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2010; 31: 143-9.
23. Billington BP. Gastric ulcer: age, sex and a curious retrogression. Aust. Ann. Med. 1960; 9: 111-21.
24. Douglas RA, Johnston ED. Aspirin and chronic gastric ulcer. Med. J. Aust. 1961; 48: 893-7.
25. Gillies MA, Skyring AP. Gastric and duodenal ulcer: the association between aspirin ingestion, smoking and family history of ulcer. Med. J. Aust. 1969; 2: 280-5.
26. Chapman BL, Duggan JM. Aspirin and uncomplicated peptic ulcer. Gut 1969; 10: 443-50.
27. Yeomans ND, Lanas AI, Talley NJ etal. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 2005; 22: 795-801.
28. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
29. Weil J, Colin-Jones D, Langman M etal. Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J. 1995; 310: 827-30.
30. de Abajo FJ, Garcia Rodriguez LA. Risks of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin. Pharmacol. 2001; 1: 1. Epub 2001 Feb 13.
31. Anonymous. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
32. Yusuf S, Zhao F, Mehta SR etal. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
33. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am. J. Med. 2001; 110 (Suppl. 1A): 62S-5S.
34. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther. 2002; 16: 1945-53.
35. Chan FKL, Chung SCS, Suen BY etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001; 344: 967-73.
36. Lai KC, Lam SK, Chu KM etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033-8.
37. Hernandéz-Díaz S, García-Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006; 4: 22-9.
38. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin. Drug Saf. 2010 (in press).
39. Smecuol E, Pinto Sanchez MI, Suarez A etal. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin. Gastroenterol. Hepatol. 2009; 7: 524-9.
40. Shiotani A, Haruma K, Nishi R etal. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking enteric-coated aspirin: low-dose aspirin-induced small bowel damage. Scand. J. Gastroenterol. 2010; 45: 292-8.
41. Yeomans ND, Lanas A, Labenz J etal. Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 2008; 103: 2465-73.
42. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2002; 16: 779-86.
43. Malfertheiner P, Megraud F, O'Morain C etal. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007; 56: 772-81.
44. Lanza FL, Chan FKL, Quigley EMM, the Practice Parameters Committee of American College of Gastroenterology. Guidelines for preventing NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104: 728-38.
45. Elliott SL, Yeomans ND, Buchanan RRC, Smallwood RA. Efficacy of 12months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo controlled trial. Scand. J. Gastroenterol. 1994; 23: 171-6.
46. Silverstein FE, Graham DY, Senior JR etal. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1995; 123: 241-9.
47. Hawkey CJ, Karrasch JA, Szczepañski L etal. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1998; 338: 727-34.
48. Graham DY, Agrawal NM, Campbell DR etal. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch. Intern Med. 2002; 162: 169-75.
49. Taha AS, Hudson N, Hawkey CJ etal. Famotidine for the prevention of gastric and duodenal ulcers caused by non steroidal antiinflammatory drugs. N. Engl. J. Med. 1996; 334: 1435-9.
50. Yeomans ND, Tulassay Z, Juhász L etal. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1998; 338: 719-26.
51. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 93-4.
52. Lanas A, Garcia Rodriguez LA, Arroyo MT etal. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.
53. Scheiman JM, van Rensburg CJ, Uebel P etal. Prevention of low-dose acetylsalicylic acid-associated gastric/duodenal ulcers with esomeprazole 20mg and 40mg once daily in patients at increased risk of ulcer development: a randomised controlled trial (OBERON). Gastroenterology 2009; 136: A70.
54. Bhatt DL, Scheiman J, Abraham NS etal. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 2008; 103: 2890-907.